This review, in addition to updating the growing list of type 1 diabetes–relevant gene therapies, offers an outline of short-term objectives that can readily be met to move, at least, adenoviral and adeno-associated viral-based protocols into the clinic, first as a means of facilitating islet allografts as well as platforms with whichto introduce immunoregulatory transgenes. A wide array of genes have been tested to restore insulin production, to drive the differentiation of insulin-producing progenitors, and to confer immunosuppression in an antigen- and tissue-restricted manner.
|Numero di pagine||7|
|Stato di pubblicazione||Published - 2006|
All Science Journal Classification (ASJC) codes